Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × tipifarnib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 16 Breast Neoplasms 11 Leukemia, Myelomonocytic, Acute 10 Leukemia, Monocytic, Acute 10 Leukemia, Megakaryoblastic, Acute 10 Leukemia, Erythroblastic, Acute 10 Congenital Abnormalities 8 Leukemia 7 Recurrence 6 Pancreatic Neoplasms 5 Multiple Myeloma 5 Leukemia, Myelomonocytic, Chronic 5 Leukemia, Eosinophilic, Acute 5 Leukemia, Basophilic, Acute 5 Glioblastoma 5 Carcinoma, Non-Small-Cell Lung 5 Anemia, Refractory, with Excess of Blasts 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma, Non-Hodgkin 4 Lymphoma 4 Gliosarcoma 4 Breast Neoplasms, Male 4 Brain Neoplasms 4 Blast Crisis 4 Urinary Bladder Neoplasms 3 Unspecified Adult Solid Tumor, Protocol Specific 3 Neuroblastoma 3 Melanoma 3 Lymphoma, Mantle-Cell 3 Lung Neoplasms 3

Interventions

osimertinib 11 Pemetrexed 11 Carboplatin 11 aflutinib 8 Gefitinib 8 Drug Therapy 8 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 pembrolizumab 4 icotinib 4 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Kura Oncology, Inc.

Phase 1 Withdrawn

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡